801
|
Hotta Y, Sasaki S, Konishi M, Kinoshita H, Kuwahara K, Nakao K, Itoh N. Fgf16 is required for cardiomyocyte proliferation in the mouse embryonic heart. Dev Dyn 2008; 237:2947-54. [DOI: 10.1002/dvdy.21726] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
|
802
|
Affiliation(s)
- Martin H Dominguez
- Department of Neurobiology and Kavli Institute for Neuroscience, Yale University School of Medicine, New Haven, Connecticut 06510, USA
| | | |
Collapse
|
803
|
Kuro-o M. Endocrine FGFs and Klothos: emerging concepts. Trends Endocrinol Metab 2008; 19:239-45. [PMID: 18692401 DOI: 10.1016/j.tem.2008.06.002] [Citation(s) in RCA: 105] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/01/2008] [Revised: 04/09/2008] [Accepted: 06/09/2008] [Indexed: 01/03/2023]
Abstract
Endocrine fibroblast growth factors (FGFs) control a variety of physiological processes including suppression of bile acid synthesis in hepatocytes, promotion of lipolysis in adipocytes, and inhibition of phosphate reabsorption and vitamin D biosynthesis in renal tubular cells. Endocrine FGFs require the Klotho gene family of transmembrane proteins as co-receptors to bind cognate FGF receptors. Importantly, expression of endocrine FGFs is regulated by nuclear receptors whose lipophilic ligands are generated under the control of these hormones in their target organs. Thus, novel endocrine axes have emerged that regulate diverse metabolic processes through feedback loops composed of the FGF, Klotho, and nuclear receptor gene families. This review covers roles of Klotho family proteins in the regulation of activity and expression of endocrine FGFs.
Collapse
Affiliation(s)
- Makoto Kuro-o
- Department of Pathology, The University of Texas Southwestern Medical Center at Dallas, 6000 Harry Hines Blvd, Dallas, TX 75390-9072, USA.
| |
Collapse
|
804
|
Motomura K, Hagiwara A, Komi-Kuramochi A, Hanyu Y, Honda E, Suzuki M, Kimura M, Oki J, Asada M, Sakaguchi N, Nakayama F, Akashi M, Imamura T. An FGF1:FGF2 chimeric growth factor exhibits universal FGF receptor specificity, enhanced stability and augmented activity useful for epithelial proliferation and radioprotection. Biochim Biophys Acta Gen Subj 2008; 1780:1432-40. [PMID: 18760333 DOI: 10.1016/j.bbagen.2008.08.001] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2008] [Revised: 07/18/2008] [Accepted: 08/06/2008] [Indexed: 10/21/2022]
Abstract
Structural instability of wild-type fibroblast growth factor (FGF)-1 and its dependence on exogenous heparin for optimal activity diminishes its potential utility as a therapeutic agent. Here we evaluated FGFC, an FGF1:FGF2 chimeric protein, for its receptor affinity, absolute heparin-dependence, stability and potential clinical applicability. Using BaF3 transfectants overexpressing each FGF receptor (FGFR) subtype, we found that, like FGF1, FGFC activates all of the FGFR subtypes (i.e., FGFR1c, FGFR1b, FGFR2c, FGFR2b, FGFR3c, FGFR3b and FGFR4) in the presence of heparin. Moreover, FGFC activates FGFRs even in the absence of heparin. FGFC stimulated keratinocytes proliferation much more strongly than FGF2, as would be expected from its ability to activate FGFR2b. FGFC showed greater structural stability, biological activity and resistance to trypsinization, and less loss in solution than FGF1 or FGF2. When FGFC was intraperitoneally administered to BALB/c mice prior to whole body gamma-irradiation, survival of small intestine crypts was significantly enhanced, as compared to control mice. These results suggest that FGFC could be useful in a variety of clinical applications, including promotion of wound healing and protection against radiation-induced damage.
Collapse
Affiliation(s)
- Kaori Motomura
- Signaling Molecules Research Group, Neuroscience Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8566, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
805
|
Falardeau J, Chung WC, Beenken A, Raivio T, Plummer L, Sidis Y, Jacobson-Dickman EE, Eliseenkova AV, Ma J, Dwyer A, Quinton R, Na S, Hall JE, Huot C, Alois N, Pearce SH, Cole LW, Hughes V, Mohammadi M, Tsai P, Pitteloud N. Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J Clin Invest 2008; 118:2822-31. [PMID: 18596921 PMCID: PMC2441855 DOI: 10.1172/jci34538] [Citation(s) in RCA: 252] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2007] [Accepted: 05/21/2008] [Indexed: 12/18/2022] Open
Abstract
Idiopathic hypogonadotropic hypogonadism (IHH) with anosmia (Kallmann syndrome; KS) or with a normal sense of smell (normosmic IHH; nIHH) are heterogeneous genetic disorders associated with deficiency of gonadotropin-releasing hormone (GnRH). While loss-of-function mutations in FGF receptor 1 (FGFR1) cause human GnRH deficiency, to date no specific ligand for FGFR1 has been identified in GnRH neuron ontogeny. Using a candidate gene approach, we identified 6 missense mutations in FGF8 in IHH probands with variable olfactory phenotypes. These patients exhibited varied degrees of GnRH deficiency, including the rare adult-onset form of hypogonadotropic hypogonadism. Four mutations affected all 4 FGF8 splice isoforms (FGF8a, FGF8b, FGF8e, and FGF8f), while 2 mutations affected FGF8e and FGF8f isoforms only. The mutant FGF8b and FGF8f ligands exhibited decreased biological activity in vitro. Furthermore, mice homozygous for a hypomorphic Fgf8 allele lacked GnRH neurons in the hypothalamus, while heterozygous mice showed substantial decreases in the number of GnRH neurons and hypothalamic GnRH peptide concentration. In conclusion, we identified FGF8 as a gene implicated in GnRH deficiency in both humans and mice and demonstrated an exquisite sensitivity of GnRH neuron development to reductions in FGF8 signaling.
Collapse
Affiliation(s)
- John Falardeau
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Wilson C.J. Chung
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Andrew Beenken
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Taneli Raivio
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Lacey Plummer
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Yisrael Sidis
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Elka E. Jacobson-Dickman
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Anna V. Eliseenkova
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Jinghong Ma
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Andrew Dwyer
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Richard Quinton
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Sandra Na
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Janet E. Hall
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Celine Huot
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Natalie Alois
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Simon H.S. Pearce
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Lindsay W. Cole
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Virginia Hughes
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Moosa Mohammadi
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Pei Tsai
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| | - Nelly Pitteloud
- Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit, Department of Medicine, Massachusetts General Hospital (MGH), Boston, Massachusetts, USA.
Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder, Colorado, USA.
Department of Pharmacology, New York University School of Medicine, New York, New York, USA.
Institute for Human Genetics and School of Clinical Medical Sciences, and
Newcastle Teaching Hospitals, Newcastle University, Newcastle upon Tyne, United Kingdom.
Centre de Recherche du CHU Sainte-Justine, Montreal, Quebec, Canada
| |
Collapse
|
806
|
Borello U, Cobos I, Long JE, McWhirter JR, Murre C, Rubenstein JLR. FGF15 promotes neurogenesis and opposes FGF8 function during neocortical development. Neural Dev 2008; 3:17. [PMID: 18625063 PMCID: PMC2492847 DOI: 10.1186/1749-8104-3-17] [Citation(s) in RCA: 108] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2008] [Accepted: 07/14/2008] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Growth, differentiation and regional specification of telencephalic domains, such as the cerebral cortex, are regulated by the interplay of secreted proteins produced by patterning centers and signal transduction systems deployed in the surrounding neuroepithelium. Among other signaling molecules, members of the fibroblast growth factor (FGF) family have a prominent role in regulating growth, differentiation and regional specification. In the mouse telencephalon the rostral patterning center expresses members of the Fgf family (Fgf8, Fgf15, Fgf17, Fgf18). FGF8 and FGF17 signaling have major roles in specification and morphogenesis of the rostroventral telencephalon, whereas the functions of FGF15 and FGF18 in the rostral patterning center have not been established. RESULTS Using Fgf15-/- mutant mice, we provide evidence that FGF15 suppresses proliferation, and that it promotes differentiation, expression of CoupTF1 and caudoventral fate; thus, reducing Fgf15 and Fgf8 dosage have opposite effects. Furthermore, we show that FGF15 and FGF8 differentially phosphorylate ERK (p42/44), AKT and S6 in cultures of embryonic cortex. Finally, we show that FGF15 inhibits proliferation in cortical cultures. CONCLUSION FGF15 and FGF8 have distinct signaling properties, and opposite effects on neocortical patterning and differentiation; FGF15 promotes CoupTF1 expression, represses proliferation and promotes neural differentiation.
Collapse
Affiliation(s)
- Ugo Borello
- Nina Ireland Laboratory of Developmental Neurobiology, Department of Psychiatry, University of California, San Francisco, CA 94143, USA.
| | | | | | | | | | | |
Collapse
|
807
|
Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M, Wyhs N, Ziaugra L, Richter DJ, Trovik J, Engelsen IB, Stefansson IM, Fennell T, Cibulskis K, Zody MC, Akslen LA, Gabriel S, Wong KK, Sellers WR, Meyerson M, Greulich H. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A 2008; 105:8713-7. [PMID: 18552176 PMCID: PMC2438391 DOI: 10.1073/pnas.0803379105] [Citation(s) in RCA: 284] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Oncogenic activation of tyrosine kinases is a common mechanism of carcinogenesis and, given the druggable nature of these enzymes, an attractive target for anticancer therapy. Here, we show that somatic mutations of the fibroblast growth factor receptor 2 (FGFR2) tyrosine kinase gene, FGFR2, are present in 12% of endometrial carcinomas, with additional instances found in lung squamous cell carcinoma and cervical carcinoma. These FGFR2 mutations, many of which are identical to mutations associated with congenital craniofacial developmental disorders, are constitutively activated and oncogenic when ectopically expressed in NIH 3T3 cells. Inhibition of FGFR2 kinase activity in endometrial carcinoma cell lines bearing such FGFR2 mutations inhibits transformation and survival, implicating FGFR2 as a novel therapeutic target in endometrial carcinoma.
Collapse
Affiliation(s)
- Amit Dutt
- *Department of Medical Oncology and
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | - Helga B. Salvesen
- ‡Department of Clinical Medicine and
- §Obstetrics and Gynecology, Haukeland University Hospital, N-5020 Bergen, Norway; and
| | - Tzu-Hsiu Chen
- *Department of Medical Oncology and
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | - Alex H. Ramos
- *Department of Medical Oncology and
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | | | - Charlie Hatton
- ¶Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02115;
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | - Richard Nicoletti
- *Department of Medical Oncology and
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | - Wendy Winckler
- ¶Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02115;
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | - Rupinder Grewal
- ¶Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02115;
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | - Megan Hanna
- ¶Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02115;
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | - Nicolas Wyhs
- ¶Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02115;
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | - Liuda Ziaugra
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | | | - Jone Trovik
- ‡Department of Clinical Medicine and
- §Obstetrics and Gynecology, Haukeland University Hospital, N-5020 Bergen, Norway; and
| | - Ingeborg B. Engelsen
- ‡Department of Clinical Medicine and
- §Obstetrics and Gynecology, Haukeland University Hospital, N-5020 Bergen, Norway; and
| | - Ingunn M. Stefansson
- ‖The Gade Institute, Section for Pathology, University of Bergen, N-5020 Bergen, Norway;
- Departments of **Pathology and
| | | | | | | | - Lars A. Akslen
- ‖The Gade Institute, Section for Pathology, University of Bergen, N-5020 Bergen, Norway;
- Departments of **Pathology and
| | - Stacey Gabriel
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
| | - Kwok-Kin Wong
- *Department of Medical Oncology and
- ††Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;
| | | | - Matthew Meyerson
- *Department of Medical Oncology and
- ¶Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA 02115;
- §§Department of Pathology, Harvard Medical School, Boston, MA 02115;
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
- ¶¶To whom correspondence may be addressed. E-mail: or
| | - Heidi Greulich
- *Department of Medical Oncology and
- ††Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115;
- †The Broad Institute of MIT and Harvard, Cambridge, MA 02142;
- ¶¶To whom correspondence may be addressed. E-mail: or
| |
Collapse
|
808
|
Abstract
Tissue-specific deletion of Fgfr1 results in severe defects in the development of both hair cells and support cells (Pirvola et al., 2002). Despite the importance of Fgfr1 in this early phase of cochlear development, the timing for the requirement for FGF signaling at this stage is not known. Therefore, we investigated the requirement for FGF signaling at early stages of cochlear development using an FGF receptor inhibitor. We find that inhibition of FGF signaling from embryonic day 14 (E14) to E16 has a dramatic effect on the development of the sensory epithelium, causing a severe reduction in hair cells and support cells, similar to that reported for the Fgfr1 deletion. The effects of inhibition of FGF signaling on sensory specification are not explained by increases in cell death or changes in proliferation but lead to a rapid reduction in Pea3 and Erm and a loss of Math1 expression. We also show that a specific FGF, FGF20, is the likely ligand for FGFR1 at this sensory specification phase of cochlear development; Fgf20 is expressed at the right time and place to mediate sensory cell specification, and blocking FGF20 with a specific antibody inhibits hair cell and support cell development in a manner similar to the FGF receptor inhibitor. Our results thus define the period of FGF-dependent sensory cell specification and the ligand that mediates this step in cochlear development.
Collapse
|
809
|
Bonneh-Barkay D, Bissel SJ, Wang G, Fish KN, Nicholl GCB, Darko SW, Medina-Flores R, Murphey-Corb M, Rajakumar PA, Nyaundi J, Mellors JW, Bowser R, Wiley CA. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. THE AMERICAN JOURNAL OF PATHOLOGY 2008; 173:130-43. [PMID: 18556781 DOI: 10.2353/ajpath.2008.080045] [Citation(s) in RCA: 105] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Human immunodeficiency virus encephalitis causes dementia in acquired immune deficiency syndrome patients. Using proteomic analysis of postmortem cerebrospinal fluid (CSF) and brain tissue from the simian immunodeficiency virus primate model, we demonstrate here a specific increase in YKL-40 that was tightly associated with lentiviral encephalitis. Longitudinal analysis of CSF from simian immunodeficiency virus-infected pigtailed macaques showed an increase in YKL-40 concentration 2 to 8 weeks before death from encephalitis. This increase in YKL-40 correlated with an increase in CSF viral load; it may therefore represent a biomarker for the development of encephalitis. Analysis of banked human CSF from human immunodeficiency virus-infected patients also demonstrated a correlation between YKL-40 concentration and CSF viral load. In vitro studies demonstrated increased YKL-40 expression and secretion by macrophages and microglia but not by neurons or astrocytes. We found that YKL40 displaced extracellular matrix-bound basic fibroblast growth factor (bFGF) as well as inhibited the mitogenic activity of both fibroblast growth factor receptor 1-expressing BaF3 cells and bFGF-induced axonal branching in hippocampal cultures. Taken together, these findings demonstrate that during lentiviral encephalitis, YKL-40 may interfere with the biological activity of bFGF and potentially of other heparin-binding growth factors and chemokines that can affect neuronal function or survival.
Collapse
Affiliation(s)
- Dafna Bonneh-Barkay
- Departments of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
810
|
Abstract
Fibroblast Growth Factors (FGFs) are polypeptides with diverse activities in development and physiology. The mammalian Fgf family can be divided into the intracellular Fgf11/12/13/14 subfamily (iFGFs), the hormone-like Fgf15/21/23 subfamily (hFGFs), and the canonical Fgf subfamilies, including Fgf1/2/5, Fgf3/4/6, Fgf7/10/22, Fgf8/17/18, and Fgf9/16/20. However, all Fgfs are evolutionarily related. We propose that an Fgf13-like gene is the ancestor of the iFgf subfamily and the most likely evolutionary ancestor of the entire Fgf family. Potential ancestors of the canonical and hFgf subfamilies, Fgf4-, Fgf5-, Fgf8-, Fgf9-, Fgf10-, and Fgf15-like, appear to have derived from an Fgf13-like ancestral gene. Canonical FGFs function in a paracrine manner, while hFGFs function in an endocrine manner. We conclude that the ancestral Fgfs for these subfamilies acquired this functional diversity before the evolution of vertebrates. During the evolution of early vertebrates, the Fgf subfamilies further expanded to contain three or four members in each subfamily.
Collapse
Affiliation(s)
- Nobuyuki Itoh
- Department of Genetic Biochemistry, Kyoto University Graduate School of Pharmaceutical Sciences, Sakyo, Kyoto, Japan.
| | | |
Collapse
|
811
|
Konishi M, Nakamura H, Miwa H, Chambon P, Ornitz DM, Itoh N. Role of Fgf receptor 2c in adipocyte hypertrophy in mesenteric white adipose tissue. Mol Cell Endocrinol 2008; 287:13-9. [PMID: 18396371 DOI: 10.1016/j.mce.2008.02.010] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/16/2007] [Revised: 12/19/2007] [Accepted: 02/14/2008] [Indexed: 10/22/2022]
Abstract
Fgf receptor 2c (Fgfr2c) was expressed in mature adipocytes of mouse white adipose tissue (WAT). To examine the role of Fgfr2c in mature adipocytes, we generated adipocyte-specific Fgfr2 knockout (Fgfr2 CKO) mice. The hypertrophy impairment of adipocytes in the mesenteric WAT but not in the subcutaneous WAT and decreased plasma free fatty acid (FFA) levels were observed in Fgfr2 CKO mice. Although the expression of genes involved in adipocyte differentiation and lipid metabolism in the mesenteric WAT was essentially unchanged, the expression of uncoupling protein 2 potentially involved in energy dissipation was significantly increased. Among potential Fgf ligands for Fgfr2c, Fgf9 was preferentially expressed in the mesenteric WAT. The present findings indicate that Fgfr2c potentially activated by Fgf9 plays a role in the adipocyte hypertrophy in the mesenteric WAT and FFA metabolism and/or energy dissipation in the mesenteric WAT might be involved in the hypertrophy impairment.
Collapse
Affiliation(s)
- Morichika Konishi
- Department of Genetic Biochemistry, Kyoto University Graduate School of Pharmaceutical Sciences, Yoshida-Shimoadachi, Sakyo, Kyoto 606-8501, Japan
| | | | | | | | | | | |
Collapse
|
812
|
Kwiatkowski BA, Kirillova I, Richard RE, Israeli D, Yablonka-Reuveni Z. FGFR4 and its novel splice form in myogenic cells: Interplay of glycosylation and tyrosine phosphorylation. J Cell Physiol 2008; 215:803-17. [PMID: 18186042 DOI: 10.1002/jcp.21365] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The family of fibroblast growth factor receptors (FGFRs) is encoded by four distinct genes. FGFR1 and FGFR4 are both expressed during myogenesis, but whereas the function of FGFR1 in myoblast proliferation has been documented, the role of FGFR4 remains unknown. Here, we report on a new splice form of FGFR4 cloned from primary cultures of mouse satellite cells. This form, named FGFR4(-16), lacks the entire exon 16, resulting in a deletion within the FGFR kinase domain. Expression of FGFR4(-16) coincided with that of wild-type FGFR4 in all FGFR4-expressing tissues examined. Moreover, expression of both FGFR4 forms correlated with the onset of myogenic differentiation, as determined in mouse C2C12 cells and in the inducible myogenic system of 10T(1/2)-MyoD-ER cell line. Both endogenous and overexpressed forms of FGFR4 exhibited N-glycosylation. In contrast to FGFR1, induced homodimerization of FGFR4 proteins did not result in receptor tyrosine phosphorylation. Surprisingly, coexpression of FGFR4 forms and a chimeric FGFR1 protein resulted in FGFR4 tyrosine phosphorylation, raising the possibility that FGFR4 phosphorylation might be enabled by a heterologous tyrosine kinase activity. Collectively, the present study reveals novel characteristics of mouse FGFR4 gene products and delineates their expression pattern during myogenesis. Our findings suggest that FGFR4 functions in a distinctly different manner than the prototype FGFR during myogenic differentiation.
Collapse
Affiliation(s)
- Boguslaw A Kwiatkowski
- Department of Biological Structure, University of Washington School of Medicine, Seattle, Washington 98195, USA
| | | | | | | | | |
Collapse
|
813
|
Mori S, Wu CY, Yamaji S, Saegusa J, Shi B, Ma Z, Kuwabara Y, Lam KS, Isseroff RR, Takada YK, Takada Y. Direct binding of integrin alphavbeta3 to FGF1 plays a role in FGF1 signaling. J Biol Chem 2008; 283:18066-75. [PMID: 18441324 DOI: 10.1074/jbc.m801213200] [Citation(s) in RCA: 107] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Integrins play a role in fibroblast growth factor (FGF) signaling through cross-talk with FGF receptors (FGFRs), but the mechanism underlying the cross-talk is unknown. We discovered that FGF1 directly bound to soluble and cell-surface integrin alphavbeta3 (K(D) about 1 microm). Antagonists to alphavbeta3 (monoclonal antibody 7E3 and cyclic RGDfV) blocked this interaction. alphavbeta3 was the predominant, if not the only, integrin that bound to FGF1, because FGF1 bound only weakly to several beta1 integrins tested. We presented evidence that the CYDMKTTC sequence (the specificity loop) within the ligand-binding site of beta3 plays a role in FGF1 binding. We found that the integrin-binding site of FGF1 overlaps with the heparin-binding site but is distinct from the FGFR-binding site using docking simulation and mutagenesis. We identified an FGF1 mutant (R50E) that was defective in integrin binding but still bound to heparin and FGFR. R50E was defective in inducing DNA synthesis, cell proliferation, cell migration, and chemotaxis, suggesting that the direct integrin binding to FGF1 is critical for FGF signaling. Nevertheless, R50E induced phosphorylation of FGFR1 and FRS2alpha and activation of AKT and ERK1/2. These results suggest that the defect in R50E in FGF signaling is not in the initial activation of FGF signaling pathway components, but in the later steps in FGF signaling. We propose that R50E is a useful tool to identify the role of integrins in FGF signaling.
Collapse
Affiliation(s)
- Seiji Mori
- Department of Dermatology, School of Medicine, University of California Davis, Sacramento, CA 95817, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
814
|
Abstract
The klotho gene functions as an aging-suppressor gene that extends life span when overexpressed and accelerates aging-like phenotypes when disrupted in mice. The klotho gene encodes a single-pass transmembrane protein that binds to multiple fibroblast growth factor (FGF) receptors and functions as a co-receptor for FGF23, a bone-derived hormone that suppresses phosphate reabsorption and vitamin D biosynthesis in the kidney. In addition, the extracellular domain of Klotho protein is shed and secreted, potentially functioning as a humoral factor. The secreted Klotho protein can regulate multiple growth factor signaling pathways, including insulin/IGF-1 and Wnt, and the activity of multiple ion channels. Klotho protein also protects cells and tissues from oxidative stress, yet the precise mechanism underlying these activities remains to be determined. Thus, understanding of Klotho protein function is expected to provide new insights into the molecular basis for aging, phosphate/vitamin D metabolism, cancer and stem cell biology.
Collapse
Affiliation(s)
- Makoto Kuro-o
- Department of Pathology, The University of Texas Southwestern Medical Center at Dallas, 6000 Harry Hines Blvd., Dallas, TX 75390-9072, USA
| |
Collapse
|
815
|
Abdel-Rahman WM, Kalinina J, Shoman S, Eissa S, Ollikainen M, Elomaa O, Eliseenkova AV, Bützow R, Mohammadi M, Peltomäki P. Somatic FGF9 mutations in colorectal and endometrial carcinomas associated with membranous beta-catenin. Hum Mutat 2008; 29:390-7. [PMID: 18165946 DOI: 10.1002/humu.20653] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
We previously described striking molecular features including high frequency of membranous beta-catenin in subsets of familial colon cancers with as yet unknown predisposition. We hypothesized that such tumors might carry mutations in Wnt/beta-catenin target genes. Fibroblast growth factor 9 (FGF9) was an attractive target, as it maps to a common area of loss of heterozygosity (LOH) in colorectal carcinomas on 13q12.11. Here, we report, for the first time, the occurrence of FGF9 mutations in human cancers. We found a total of six distinct FGF9 mutations including one frameshift, four missense, and one nonsense, in 10 (six colorectal and four endometrial) out of 203 tumors and cell lines. The frameshift mutation was detected in five different tumors. Mapping of these mutations onto the crystal structure of FGF9 predicted that they should all lead to loss of function albeit through variable mechanisms. The p.R173K mutation should diminish ligand affinity for heparin/heparan sulfate, the p.V192M, p.D203G, and p.L188YfsX18 (FGF9(Delta205-208)) mutations should negatively impact ligand's interaction with receptor, while p.G84E and p.E142X (FGF9(Delta142-208)) mutations should interfere with ligand folding. Consistent with these structural predictions, the p.V192M, p.D203G, and p.L188YfsX18 (FGF9(Delta205-208)) mutations impaired the ability of ligand to activate mitogen-activated protein kinase (MAPK) cascade in cultured cells expressing FGF receptors. LOH was observed in seven out of nine FGF9 mutant tumors, supporting the predicted loss of function. Interestingly, eight out of 10 (80%) of the FGF9 mutant tumors showed normal membranous beta-catenin expression and the absence of mutation in the beta-catenin gene (CTNNB1). These data suggest that FGF9 plays a role in colorectal and endometrial carcinogenesis.
Collapse
|
816
|
Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, Elbi C, Lutterbach B. FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival. Cancer Res 2008; 68:2340-8. [DOI: 10.1158/0008-5472.can-07-5229] [Citation(s) in RCA: 205] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
817
|
Scearce-Levie K, Roberson ED, Gerstein H, Cholfin JA, Mandiyan VS, Shah NM, Rubenstein JLR, Mucke L. Abnormal social behaviors in mice lacking Fgf17. GENES BRAIN AND BEHAVIOR 2008; 7:344-54. [PMID: 17908176 DOI: 10.1111/j.1601-183x.2007.00357.x] [Citation(s) in RCA: 91] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The fibroblast growth factor family of secreted signaling molecules is essential for patterning in the central nervous system. Fibroblast growth factor 17 (Fgf17) has been shown to contribute to regionalization of the rodent frontal cortex. To determine how Fgf17 signaling modulates behavior, both during development and in adulthood, we studied mice lacking one or two copies of the Fgf17 gene. Fgf17-deficient mice showed no abnormalities in overall physical growth, activity level, exploration, anxiety-like behaviors, motor co-ordination, motor learning, acoustic startle, prepulse inhibition, feeding, fear conditioning, aggression and olfactory exploration. However, they displayed striking deficits in several behaviors involving specific social interactions. Fgf17-deficient pups vocalized less than wild-type controls when separated from their mother and siblings. Elimination of Fgf17 also decreased the interaction of adult males with a novel ovariectomized female in a social recognition test and reduced the amount of time opposite-sex pairs spent engaged in prolonged, affiliative interactions during exploration of a novel environment. After social exploration of a novel environment, Fgf17-deficient mice showed less activation of the immediate-early gene Fos in the frontal cortex than wild-type controls. Our findings show that Fgf17 is required for several complex social behaviors and suggest that disturbances in Fgf17 signaling may contribute to neuropsychiatric diseases that affect such behaviors.
Collapse
Affiliation(s)
- K Scearce-Levie
- Gladstone Institute of Neurological Disease, San Francisco, CA 94158-2261, USA.
| | | | | | | | | | | | | | | |
Collapse
|
818
|
Extracellular point mutations in FGFR2 result in elevated ERK1/2 activation and perturbation of neuronal differentiation. Biochem J 2008; 410:205-11. [PMID: 18039182 DOI: 10.1042/bj20070859] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Two independent gain-of-function point mutations (S252W and P253R) in the extracellular region of the FGFR2 (fibroblast growth factor receptor 2) increase the binding affinity for the growth factor. The effect of this enhanced growth factor binding by these mutants is expected to be an increase in activation of regular signalling pathways from FGFR2 as a result of more receptors being engaged by ligand at any given time. Using PC12 (pheochromocytoma) cells as a model cell system we investigated the effect of these mutations on protein phosphorylation including the receptor, the activation of downstream signalling pathways and cell differentiation. Our results show that the effects of both of these extracellular mutations have unexpected intracellular phenotypes and cellular responses. Receptor phosphorylation was altered in both the ligand-stimulated and unstimulated states. The mutants also resulted in differential phosphorylation of a number of intracellular proteins. Both mutations resulted in enhanced ERK1/2 (extracellular-signalregulated kinase1/2) activation. Although ERK1/2 activation is believed to transduce signals resulting in cell differentiation, this response was abrogated in the cells expressing the mutant receptors. The results of the present study demonstrate that single extracellular point mutations in the FGFR2 have a profound effect on intracellular signalling and ultimately on cell fate.
Collapse
|
819
|
Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koyama Y, Kimura M, Asada M, Komi-Kuramochi A, Oka S, Imamura T. betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 2008; 22:1006-14. [PMID: 18187602 PMCID: PMC5419549 DOI: 10.1210/me.2007-0313] [Citation(s) in RCA: 267] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2007] [Accepted: 01/03/2008] [Indexed: 01/27/2023] Open
Abstract
Fibroblast growth factor (FGF) 21, a structural relative of FGF23 that regulates phosphate homeostasis, is a regulator of insulin-independent glucose transport in adipocytes and plays a role in the regulation of body weight. It also regulates ketogenesis and adaptive responses to starvation. We report that in a reconstituted receptor activation assay system using BaF3 cells, which do not endogenously express any type of FGF receptor (FGFR) or heparan sulfate proteoglycan, FGF21 alone does not activate FGFRs and that betaKlotho is required for FGF21 to activate two specific FGFR subtypes: FGFR1c and FGFR3c. Coexpression of betaKlotho and FGFR1c on BaF3 cells enabled FGF21, but not FGF23, to activate receptor signaling. Conversely, coexpression of FGFR1c and Klotho, a protein related to betaKlotho, enabled FGF23 but not FGF21 to activate receptor signaling, indicating that expression of betaKlotho/Klotho confers target cell specificity on FGF21/FGF23. In all of these cases, heparin enhanced the activation but was not essential. In 3T3-L1 adipocytes, up-regulation of glucose transporter (GLUT) expression by FGF21 was associated with expression of betaKlotho, which was absent in undifferentiated 3T3-L1 fibroblasts. It is thus suggested that betaKlotho expression is a crucial determinant of the FGF21 specificity of the target cells upon which it acts in an endocrine fashion.
Collapse
MESH Headings
- 3T3-L1 Cells
- Animals
- Fibroblast Growth Factor-23
- Fibroblast Growth Factors/pharmacology
- Gene Expression/drug effects
- Glucose Transport Proteins, Facilitative/genetics
- Glucose Transport Proteins, Facilitative/metabolism
- Glucuronidase/genetics
- Glucuronidase/metabolism
- Immunoblotting
- Klotho Proteins
- Mice
- Protein Binding
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Receptor, Fibroblast Growth Factor, Type 1/genetics
- Receptor, Fibroblast Growth Factor, Type 1/metabolism
- Receptor, Fibroblast Growth Factor, Type 3/genetics
- Receptor, Fibroblast Growth Factor, Type 3/metabolism
- Reverse Transcriptase Polymerase Chain Reaction
- Signal Transduction
Collapse
Affiliation(s)
- Masashi Suzuki
- Signaling Molecules Research Laboratory, National Institute of Advanced Industrial Science and Technology, Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki 305-8566, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
820
|
Szabo-Rogers HL, Geetha-Loganathan P, Nimmagadda S, Fu KK, Richman JM. FGF signals from the nasal pit are necessary for normal facial morphogenesis. Dev Biol 2008; 318:289-302. [PMID: 18455717 DOI: 10.1016/j.ydbio.2008.03.027] [Citation(s) in RCA: 73] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2007] [Revised: 02/22/2008] [Accepted: 03/17/2008] [Indexed: 01/15/2023]
Abstract
Fibroblast growth factors (FGFs) are required for brain, pharyngeal arch, suture and neural crest cell development and mutations in the FGF receptors have been linked to human craniofacial malformations. To study the functions of FGF during facial morphogenesis we locally perturb FGF signalling in the avian facial prominences with FGFR antagonists, foil barriers and FGF2 protein. We tested 4 positions with antagonist-soaked beads but only one of these induced a facial defect. Embryos treated in the lateral frontonasal mass, adjacent to the nasal slit developed cleft beaks. The main mechanisms were a block in proliferation and an increase in apoptosis in those areas that were most dependent on FGF signaling. We inserted foil barriers with the goal of blocking diffusion of FGF ligands out of the lateral edge of the frontonasal mass. The barriers induced an upregulation of the FGF target gene, SPRY2 compared to the control side. Moreover, these changes in expression were associated with deletions of the lateral edge of the premaxillary bone. To determine whether we could replicate the effects of the foil by increasing FGF levels, beads soaked in FGF2 were placed into the lateral edge of the frontonasal mass. There was a significant increase in proliferation and an expansion of the frontonasal mass but the skeletal defects were minor and not the same as those produced by the foil. Instead it is more likely that the foil repressed FGF signaling perhaps mediated by the increase in SPRY2 expression. In summary, we have found that the nasal slit is a source of FGF signals and the function of FGF is to stimulate proliferation in the cranial frontonasal mass. The FGF independent regions correlate with those previously determined to be dependent on BMP signaling. We propose a new model whereby, FGF-dependent microenvironments exist in the cranial frontonasal mass and caudal maxillary prominence and these flank BMP-dependent regions. Coordination of the proliferation in these regions leads ultimately to normal facial morphogenesis.
Collapse
Affiliation(s)
- Heather L Szabo-Rogers
- Department of Oral Health Sciences, Life Sciences Institute, The University of British Columbia, 2350 Health Sciences Mall, Vancouver BC, Canada
| | | | | | | | | |
Collapse
|
821
|
Zhao H, Yang T, Madakashira BP, Thiels CA, Bechtle CA, Garcia CM, Zhang H, Yu K, Ornitz DM, Beebe DC, Robinson ML. Fibroblast growth factor receptor signaling is essential for lens fiber cell differentiation. Dev Biol 2008; 318:276-88. [PMID: 18455718 DOI: 10.1016/j.ydbio.2008.03.028] [Citation(s) in RCA: 134] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2007] [Revised: 03/14/2008] [Accepted: 03/17/2008] [Indexed: 11/19/2022]
Abstract
The vertebrate lens provides an excellent model to study the mechanisms that regulate terminal differentiation. Although fibroblast growth factors (FGFs) are thought to be important for lens cell differentiation, it is unclear which FGF receptors mediate these processes during different stages of lens development. Deletion of three FGF receptors (Fgfr1-3) early in lens development demonstrated that expression of only a single allele of Fgfr2 or Fgfr3 was sufficient for grossly normal lens development, while mice possessing only a single Fgfr1 allele developed cataracts and microphthalmia. Profound defects were observed in lenses lacking all three Fgfrs. These included lack of fiber cell elongation, abnormal proliferation in prospective lens fiber cells, reduced expression of the cell cycle inhibitors p27(kip1) and p57(kip2), increased apoptosis and aberrant or reduced expression of Prox1, Pax6, c-Maf, E-cadherin and alpha-, beta- and gamma-crystallins. Therefore, while signaling by FGF receptors is essential for lens fiber differentiation, different FGF receptors function redundantly.
Collapse
MESH Headings
- Animals
- Cell Differentiation
- Cell Enlargement
- Cyclin-Dependent Kinase Inhibitor p27/metabolism
- Cyclin-Dependent Kinase Inhibitor p57/metabolism
- Eye Abnormalities/embryology
- Fibroblast Growth Factors/metabolism
- Gene Targeting
- Homeodomain Proteins/metabolism
- Lens, Crystalline/cytology
- Lens, Crystalline/embryology
- Mice
- Mutation
- Proto-Oncogene Proteins c-maf/metabolism
- Receptor, Fibroblast Growth Factor, Type 1/genetics
- Receptor, Fibroblast Growth Factor, Type 1/metabolism
- Receptor, Fibroblast Growth Factor, Type 2/genetics
- Receptor, Fibroblast Growth Factor, Type 2/metabolism
- Receptor, Fibroblast Growth Factor, Type 3/genetics
- Receptor, Fibroblast Growth Factor, Type 3/metabolism
- Signal Transduction
- Tumor Suppressor Proteins/metabolism
Collapse
Affiliation(s)
- Haotian Zhao
- Graduate Program in Molecular, Cellular and Developmental Biology, College of Biological Sciences, The Ohio State University, Columbus, OH 43210, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
822
|
Lu SY, Sontag DP, Detillieux KA, Cattini PA. FGF-16 is released from neonatal cardiac myocytes and alters growth-related signaling: a possible role in postnatal development. Am J Physiol Cell Physiol 2008; 294:C1242-9. [PMID: 18337564 DOI: 10.1152/ajpcell.00529.2007] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
FGF-16 has been reported to be preferentially expressed in the adult rat heart. We have investigated the expression of FGF-16 in the perinatal and postnatal heart and its functional significance in neonatal rat cardiac myocytes. FGF-16 mRNA accumulation was observed by quantitative RT-PCR between neonatal days 1 and 7, with this increased expression persisting into adulthood. FGF-2 has been shown to increase neonatal rat cardiac myocyte proliferative potential via PKC activation. Gene array analysis revealed that FGF-16 inhibited the upregulation by FGF-2 of cell cycle promoting genes including cyclin F and Ki67. Furthermore, the CDK4/6 inhibitor gene Arf/INK4A was upregulated with the combination of FGF-16 and FGF-2 but not with either factor on its own. The effect on Ki67 was validated by protein immunodetection, which also showed that FGF-16 significantly decreased FGF-2-induced Ki67 labeling of cardiac myocytes, although it alone had no effect on Ki67 labeling. Inhibition of p38 MAPK potentiated cardiac myocyte proliferation induced by FGF-2 but did not alter the inhibitory action of FGF-16. Receptor binding assay showed that FGF-16 can compete with FGF-2 for binding sites including FGF receptor 1. FGF-16 had no effect on activated p38, ERK1/2, or JNK/SAPK after FGF-2 treatment. However, FGF-16 inhibited PKC-alpha and PKC-epsilon activation induced by FGF-2 and, importantly, IGF-1. Collectively, these data suggest that expression and release of FGF-16 in the neonatal myocardium interfere with cardiac myocyte proliferative potential by altering the local signaling environment via modulation of PKC activation and cell cycle-related gene expression.
Collapse
Affiliation(s)
- Shun Yan Lu
- Department of Physiology, University of Manitoba, Winnipeg, Manitoba, Canada R3E 3J7
| | | | | | | |
Collapse
|
823
|
Knowles MA. Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. Future Oncol 2008; 4:71-83. [PMID: 18241002 DOI: 10.2217/14796694.4.1.71] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
Bladder cancer presents several challenges in clinical management. For the large group of noninvasive tumors, key problems are the development of multiple recurrences that require long-term surveillance and a lack of effective therapies to prevent recurrence. For the smaller group of poor prognosis patients with invasive disease, novel therapies are urgently needed. The identification of mutations of FGF receptor 3 (FGFR3) in most noninvasive bladder tumors and the recent finding of overexpression of this receptor not only in superficial tumors but also in many invasive bladder cancers has generated optimism that therapies targeting this receptor tyrosine kinase may have major application in the treatment of urothelial cancers. There is little information on the other members of this receptor family apart from FGFR2, which is implicated as a tumor suppressor. Recent preclinical evaluations of FGFR3 as a therapeutic target have provided a strong impetus for the development of targeted agents for clinical use.
Collapse
Affiliation(s)
- Margaret A Knowles
- Cancer Research UK Clinical Centre, Section of Oncology, Leeds Institute of Molecular Medicine, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK.
| |
Collapse
|
824
|
Li S, Christensen C, Kiselyov VV, Køhler LB, Bock E, Berezin V. Fibroblast growth factor-derived peptides: functional agonists of the fibroblast growth factor receptor. J Neurochem 2008; 104:667-82. [PMID: 18199118 DOI: 10.1111/j.1471-4159.2007.05070.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
A series of peptides, termed dekafins, were derived from the beta10-beta11 loop regions of fibroblast growth factors (FGFs) 1, 2, 3, 5, 6, 8, 9, 10, and 17. The dekafins share a homologous amino acid sequence similar to a sequence in the first fibronectin type III module of the neural cell adhesion molecule. All dekafins were shown by surface plasmon resonance analysis to bind fibroblast growth factor receptor (FGFR)1-IIIc-Ig2-3 and FGFR2-IIIb-Ig2-3, respectively, with K(d) values of approximately 10(-7) to 10(-8) mol/L. Binding of dekafin1 to FGFR1-IIIc-Ig2-3 was inhibited by a heparin analog, sucrose octasulfate, indicating that heparin sulfate moiety can modulate dekafin binding to FGFRs. Treatment of transcription and mRNA export (TREX) cells permanently expressing Strep-tag-labeled FGFR1-IIIc with dekafins resulted in receptor phosphorylation. FGF1-induced FGFR1-IIIc phosphorylation was inhibited by dekafin1 and 10 in high concentrations, indicating that dekafins are FGFR partial agonists. The dekafins induced neuronal differentiation as reflected by neurite outgrowth from cerebellar granule neurons, an effect that was abolished by SU5402, a specific inhibitor of the FGFR tyrosine kinase, and by inositolhexaphosphate, an extracellularly acting FGFR antagonist. Some, but not all, dekafins were capable of promoting survival of cerebellar granule neurons induced to undergo apoptosis. Thus, the dekafins are functional FGFR agonists with apparent therapeutic potential.
Collapse
Affiliation(s)
- Shizhong Li
- Protein Laboratory, Department of Neuroscience and Pharmacology, Faculty of Health Sciences, University of Copenhagen, Copenhagen N, Denmark, and ENKAM Pharmaceuticals A/S, Copenhagen Ø, Denmark
| | | | | | | | | | | |
Collapse
|
825
|
Sugaya N, Habuchi H, Nagai N, Ashikari-Hada S, Kimata K. 6-O-sulfation of heparan sulfate differentially regulates various fibroblast growth factor-dependent signalings in culture. J Biol Chem 2008; 283:10366-76. [PMID: 18281280 DOI: 10.1074/jbc.m705948200] [Citation(s) in RCA: 88] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Heparan sulfate (HS) interacts with diverse heparin-binding growth factors and thereby regulates their bioactivities. These interactions depend on the structures characterized by the sulfation pattern and isomer of uronic acid residues. One of the biosynthetic modifications of HS, namely 6-O-sulfation, is catalyzed by three isoforms of HS6-O-sulfotransferase. We generated HS6ST-1- and/or HS6ST-2-deficient mice (6ST1-KO, 6ST2-KO, and double knock-out (dKO)) that exhibited different phenotypes. We examined the effects of HS 6-O-sulfation in heparin-binding growth factor signaling using fibroblasts derived from these mutant mice. Mouse embryonic fibroblasts (MEF) prepared from E14.5 dKO mice produced HS with little 6-O-sulfate, whereas 2-O-sulfation in HS from dKO-MEF (dKO-HS) was increased by 1.9-fold. HS6-O-sulfotransferase activity in the dKO-MEF was hardly detected, and HS2-O-sulfotransferase activity was 1.5-fold higher than that in wild type (WT)-MEFs. The response of dKO-MEFs to fibroblast growth factors (FGFs) was distinct from that of WT-MEFs; in dKO-MEFs, FGF-4- and FGF-2-dependent signalings were reduced to approximately 30 and 60% of WT-MEFs, respectively, and FGF-1-dependent signaling was moderately reduced compared with that of WT-MEFs but only at the lower FGF-1 concentrations. Analysis with a surface plasmon resonance biosensor demonstrated that the apparent affinity of dKO-HS for FGF-4 was markedly reduced and was also reduced for FGF-1. In contrast, the affinity of dKO-HS for FGF-2 was 2.5-fold higher than that of HS from WT-MEFs. Thus, 6-O-sulfate in HS may regulate the signalings of some of HB-GFs, including FGFs, by inducing different interactions between ligands and their receptors.
Collapse
Affiliation(s)
- Noriko Sugaya
- Institute for Molecular Science of Medicine, Aichi Medical University, Nagakute, Aichi 480-1195, Japan
| | | | | | | | | |
Collapse
|
826
|
Goodger SJ, Robinson CJ, Murphy KJ, Gasiunas N, Harmer NJ, Blundell TL, Pye DA, Gallagher JT. Evidence that heparin saccharides promote FGF2 mitogenesis through two distinct mechanisms. J Biol Chem 2008; 283:13001-8. [PMID: 18281281 DOI: 10.1074/jbc.m704531200] [Citation(s) in RCA: 73] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Heparin-like saccharides play an essential role in binding to both fibroblast growth factors (FGF) and their receptors at the cell surface. In this study we prepared a series of heparin oligosaccharides according to their size and sulfation level. We then investigated their affinity for FGF2 and their ability to support FGF2 mitogenesis of heparan sulfate-deficient cells expressing FGFR1c. Tetra- and hexasaccharides bound FGF2, but failed to dimerize the growth factor. Nevertheless, these saccharides promoted FGF2-mediated cell growth. Furthermore, whereas enzymatic removal of the non-reducing end 2-O-sulfate group had little effect on the 1:1 interaction with FGF2, it eliminated the mitogenic activity of these saccharides. This evidence supports the symmetric two-end model of ternary complex formation. In contrast, even at very low concentrations, octasaccharide and larger heparin fragments conferred a potent mitogenic activity that was independent of terminal 2-O-sulfation. This correlated with the ability to dimerize FGF2 in an apparently cooperative manner. This data suggests that potent mitogenic signaling results from heparin-mediated trans-dimerization of FGF2, consistent with the asymmetric model of ternary complex formation. We propose that, depending on saccharide structure, there are different architectures and modes of ternary complex assembly that differ in stability and/or efficiency of transmembrane signaling.
Collapse
Affiliation(s)
- Sarah J Goodger
- Paterson Institute for Cancer Research, University of Manchester, Manchester M20 4BX, UK
| | | | | | | | | | | | | | | |
Collapse
|
827
|
Havens BA, Velonis D, Kronenberg MS, Lichtler AC, Oliver B, Mina M. Roles of FGFR3 during morphogenesis of Meckel's cartilage and mandibular bones. Dev Biol 2008; 316:336-49. [PMID: 18339367 DOI: 10.1016/j.ydbio.2008.01.035] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2007] [Revised: 01/18/2008] [Accepted: 01/22/2008] [Indexed: 10/22/2022]
Abstract
To address the functions of FGFR2 and FGFR3 signaling during mandibular skeletogenesis, we over-expressed in the developing chick mandible, replication-competent retroviruses carrying truncated FGFR2c or FGFR3c that function as dominant negative receptors (RCAS-dnFGFR2 and RCAS-dnFGFR3). Injection of RCAS-dnFGFR3 between HH15 and 20 led to reduced proliferation, increased apoptosis, and decreased differentiation of chondroblasts in Meckel's cartilage. These changes resulted in the formation of a hypoplastic mandibular process and truncated Meckel's cartilage. This treatment also affected the proliferation and survival of osteoprogenitor cells in osteogenic condensations, leading to the absence of five mandibular bones on the injected side. Injection of RCAS-dnFGFR2 between HH15 and 20 or RCAS-dnFGFR3 at HH26 did not affect the morphogenesis of Meckel's cartilage but resulted in truncations of the mandibular bones. RCAS-dnFGFR3 affected the proliferation and survival of the cells within the periosteum and osteoblasts. Together these results demonstrate that FGFR3 signaling is required for the elongation of Meckel's cartilage and FGFR2 and FGFR3 have roles during intramembranous ossification of mandibular bones.
Collapse
Affiliation(s)
- Bruce A Havens
- Department of Craniofacial Sciences, School of Dental Medicine, University of Connecticut Health Center, Farmington, CT 06030, USA
| | | | | | | | | | | |
Collapse
|
828
|
Yu K, Ornitz DM. FGF signaling regulates mesenchymal differentiation and skeletal patterning along the limb bud proximodistal axis. Development 2008; 135:483-91. [DOI: 10.1242/dev.013268] [Citation(s) in RCA: 103] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Fibroblast growth factors (FGFs) are signals from the apical ectodermal ridge (AER) that are essential for limb pattern formation along the proximodistal (PD) axis. However, how patterning along the PD axis is regulated by AER-FGF signals remains controversial. To further explore the molecular mechanism of FGF functions during limb development, we conditionally inactivated fgf receptor 2 (Fgfr2) in the mouse AER to terminate all AER functions; for comparison, we inactivated both Fgfr1 and Fgfr2 in limb mesenchyme to block mesenchymal AER-FGF signaling. We also re-examined published data in which Fgf4 and Fgf8 were inactivated in the AER. We conclude that limb skeletal phenotypes resulting from loss of AER-FGF signals cannot simply be a consequence of excessive mesenchymal cell death, as suggested by previous studies, but also must be a consequence of reduced mesenchymal proliferation and a failure of mesenchymal differentiation, which occur following loss of both Fgf4 and Fgf8. We further conclude that chondrogenic primordia formation,marked by initial Sox9 expression in limb mesenchyme, is an essential component of the PD patterning process and that a key role for AER-FGF signaling is to facilitate SOX9 function and to ensure progressive establishment of chondrogenic primordia along the PD axis.
Collapse
Affiliation(s)
- Kai Yu
- Department of Developmental Biology, Washington University School of Medicine, St Louis, MO 63110 USA
| | - David M. Ornitz
- Department of Developmental Biology, Washington University School of Medicine, St Louis, MO 63110 USA
| |
Collapse
|
829
|
Kim SH, Hu Y, Cadman S, Bouloux P. Diversity in fibroblast growth factor receptor 1 regulation: learning from the investigation of Kallmann syndrome. J Neuroendocrinol 2008; 20:141-63. [PMID: 18034870 DOI: 10.1111/j.1365-2826.2007.01627.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The unravelling of the genetic basis of the hypogonadotrophic hypogonadal disorders, including Kallmann syndrome (KS), has led to renewed interest into the developmental biology of gonadotrophin-releasing hormone (GnRH) neurones and, more generally, into the molecular mechanisms of reproduction. KS is characterised by the association of GnRH deficiency with diminished olfaction. Until recently, only two KS-associated genes were known: KAL1 and KAL2. KAL1 encodes the cell membrane and extracellular matrix-associated secreted protein anosmin-1 which is implicated in the X-linked form of KS. Anosmin-1 shows high affinity binding to heparan sulphate (HS) and its function remains the focus of ongoing investigation, although a role in axonal guidance and neuronal migration, which are processes essential for normal GnRH ontogeny and olfactory bulb histogenesis, has been suggested. KAL2, identified as the fibroblast growth factor receptor 1 (FGFR1) gene, has now been recognised to be the underlying genetic defect for an autosomal dominant form of KS. The diverse signalling pathways initiated upon FGFR activation can elicit pleiotropic cellular responses depending on the cellular context. Signalling through FGFR requires HS for receptor dimerisation and ligand binding. Current evidence supports a HS-dependent interaction between anosmin-1 and FGFR1, where anosmin-1 serves as a co-ligand activator enhancing the signal activity, the finer details of whose mechanism remain the subject of intense investigation. Recently, mutations in the genes encoding prokineticin 2 (PK2) and prokineticin receptor 2 (PKR2) were reported in a cohort of KS patients, further reinforcing the view of KS as a multigenic trait involving divergent pathways. Here, we review the historical and current understandings of KS and discuss the latest findings from the molecular and cellular studies of the KS-associated proteins, and describe the evidence that suggests convergence of several of these pathways during normal GnRH and olfactory neuronal ontogeny.
Collapse
Affiliation(s)
- S-H Kim
- Centre for Neuroendocrinology, Royal Free and University College Medical School, University College London, London, UK.
| | | | | | | |
Collapse
|
830
|
Fritzsch B, Beisel KW, Pauley S, Soukup G. Molecular evolution of the vertebrate mechanosensory cell and ear. THE INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY 2008; 51:663-78. [PMID: 17891725 PMCID: PMC3918877 DOI: 10.1387/ijdb.072367bf] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
The molecular basis of mechanosensation, mechanosensory cell development and mechanosensory organ development is reviewed with an emphasis on its evolution. In contrast to eye evolution and development, which apparently modified a genetic program through intercalation of genes between the master control genes on the top (Pax6, Eya1, Six1) of the hierarchy and the structural genes (rhodopsin) at the bottom, the as yet molecularly unknown mechanosensory channel precludes such a firm conclusion for mechanosensors. However, recent years have seen the identification of several structural genes which are involved in mechanosensory tethering and several transcription factors controlling mechanosensory cell and organ development; these warrant the interpretation of available data in very much the same fashion as for eye evolution: molecular homology combined with potential morphological parallelism. This assertion of molecular homology is strongly supported by recent findings of a highly conserved set of microRNAs that appear to be associated with mechanosensory cell development across phyla. The conservation of transcription factors and their regulators fits very well to the known or presumed mechanosensory specializations which can be mostly grouped as variations of a common cellular theme. Given the widespread distribution of the molecular ability to form mechanosensory cells, it comes as no surprise that structurally different mechanosensory organs evolved in different phyla, presenting a variation of a common theme specified by a conserved set of transcription factors in their cellular development. Within vertebrates and arthropods, some mechanosensory organs evolved into auditory organs, greatly increasing sensitivity to sound through modifications of accessory structures to direct sound to the specific sensory epithelia. However, while great attention has been paid to the evolution of these accessory structures in vertebrate fossils, comparatively less attention has been spent on the evolution of the inner ear and the central auditory system. Recent advances in our molecular understanding of ear and brain development provide novel avenues to this neglected aspect of auditory neurosensory evolution.
Collapse
Affiliation(s)
- Bernd Fritzsch
- Creighton University, Dept of Biomedical Sciences, Omaha, NE 68178, USA.
| | | | | | | |
Collapse
|
831
|
Patel VN, Likar KM, Zisman-Rozen S, Cowherd SN, Lassiter KS, Sher I, Yates EA, Turnbull JE, Ron D, Hoffman MP. Specific heparan sulfate structures modulate FGF10-mediated submandibular gland epithelial morphogenesis and differentiation. J Biol Chem 2008; 283:9308-17. [PMID: 18230614 DOI: 10.1074/jbc.m709995200] [Citation(s) in RCA: 85] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
FGF10, a heparan sulfate (HS)-binding growth factor, is required for branching morphogenesis of mouse submandibular glands (SMGs). HS increases the affinity of FGF10 for FGFR2b, which forms an FGF10.FGFR2b.HS ternary signaling complex, and results in diverse biological outcomes, including proliferation and epithelial morphogenesis. Defining the HS structures involved in specific FGF10-mediated events is critical to understand how HS modulates growth factor signaling in specific developmental contexts. We used HS-deficient BaF3/FGFR2b cells, which require exogenous HS to proliferate, to investigate the HS requirements for FGF10-mediated proliferation and primary SMG epithelia to investigate the structural requirements of HS for FGF10-mediated epithelial morphogenesis. In BaF3/FGFR2b cells, heparin with at least 10 saccharides and 6-O-, 2-O-, and N-sulfates were required for maximal proliferation. During FGF10-mediated SMG epithelial morphogenesis, HS increased proliferation and end bud expansion. Defined heparin decasaccharide libraries showed that 2-O-sulfation with either an N-or 6-O-sulfate induced end bud expansion, whereas decasaccharides with 6-O-sulfation alone induced duct elongation. End bud expansion resulted from increased FGFR1b signaling, with increased FGFR1b, Fgf1, and Spry1 as well as increased Aqp5 expression, a marker of end bud differentiation. Duct elongation was associated with expression of Cp2L1, a marker of developing ducts. Collectively, these findings show that the size and sulfate patterns of HS modulate specific FGF10-mediated events, such as proliferation, duct elongation, end bud expansion, and differentiation, and provide mechanistic insight as to how the developmental localization of specific HS structures in tissues influences FGF10-mediated morphogenesis and differentiation.
Collapse
Affiliation(s)
- Vaishali N Patel
- Matrix and Morphogenesis Unit, Laboratory of Cell and Developmental Biology, National Institute of Dental and Craniofacial Research, National Institutes of Health/DHHS, 30 Convent Drive, Bethesda, MD 20892, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
832
|
Basson MA, Echevarria D, Ahn CP, Sudarov A, Joyner AL, Mason IJ, Martinez S, Martin GR. Specific regions within the embryonic midbrain and cerebellum require different levels of FGF signaling during development. Development 2008; 135:889-98. [PMID: 18216176 DOI: 10.1242/dev.011569] [Citation(s) in RCA: 107] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Prospective midbrain and cerebellum formation are coordinated by FGF ligands produced by the isthmic organizer. Previous studies have suggested that midbrain and cerebellum development require different levels of FGF signaling. However, little is known about the extent to which specific regions within these two parts of the brain differ in their requirement for FGF signaling during embryogenesis. Here, we have explored the effects of inhibiting FGF signaling within the embryonic mouse midbrain (mesencephalon) and cerebellum (rhombomere 1) by misexpressing sprouty2 (Spry2) from an early stage. We show that such Spry2 misexpression moderately reduces FGF signaling, and that this reduction causes cell death in the anterior mesencephalon, the region furthest from the source of FGF ligands. Interestingly, the remaining mesencephalon cells develop into anterior midbrain, indicating that a low level of FGF signaling is sufficient to promote only anterior midbrain development. Spry2 misexpression also affects development of the vermis, the part of the cerebellum that spans the midline. We found that, whereas misexpression of Spry2 alone caused loss of the anterior vermis, reducing FGF signaling further, by decreasing Fgf8 gene dose, resulted in loss of the entire vermis. Our data suggest that cell death is not responsible for vermis loss, but rather that it fails to develop because reducing FGF signaling perturbs the balance between vermis and roof plate development in rhombomere 1. We suggest a molecular explanation for this phenomenon by providing evidence that FGF signaling functions to inhibit the BMP signaling that promotes roof plate development.
Collapse
Affiliation(s)
- M Albert Basson
- Department of Anatomy and Program in Developmental Biology, University of California-San Francisco, CA 94158, USA
| | | | | | | | | | | | | | | |
Collapse
|
833
|
Abstract
Fibroblast growth factor (FGF) 19 is an atypical member of the fibroblast growth factor family of signaling molecules. FGF19, FGF21, and FGF23 comprise a phylogenetic subfamily with attributes that distinguish them from typical FGFs. The FGF19 subfamily has reduced heparin binding resulting from a disrupted beta-trefoil domain. Reduced heparin binding allows these FGFs to diffuse beyond their site of origin and act as endocrine hormones. This family of FGFs is regulated, at least in part, by nuclear hormone receptors. FGF19 expression is regulated by the farnesoid X receptor, a nuclear hormone receptor that is a key regulator of bile acid biosynthesis and transport. In line with its regulation by a bile acid receptor, FGF19 is involved in the regulation of bile acid biosynthesis and gallbladder filling. FGF19 originates from intestine and signals to liver via the portal circulation with a pronounced diurnal pattern. FGF19 is the only FGF to not have a closely related mouse homologue. The mouse homologue of FGF19, called FGF15, is only 53% identical to the human FGF19. FGF19 transgenic mice and mice administered exogenous FGF19 are resistant to the effects of a high fat diet, suggesting FGF19 may play a role in metabolic signaling pathways. Hepatocellular carcinoma is seen in mice, predominantly female mice, exposed to FGF19. Further investigation into the cellular mechanisms involved in these activities will allow better understanding of FGF19 biology in the context of human physiology.
Collapse
Affiliation(s)
- Stacey Jones
- Discovery Technology Group, Research & Development, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, North Carolina 27709, USA.
| |
Collapse
|
834
|
Guerra DM, Giometti IC, Price CA, Andrade PB, Castilho AC, Machado MF, Ripamonte P, Papa PC, Buratini J. Expression of fibroblast growth factor receptors during development and regression of the bovine corpus luteum. Reprod Fertil Dev 2008; 20:659-64. [DOI: 10.1071/rd07114] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2007] [Accepted: 04/21/2008] [Indexed: 11/23/2022] Open
Abstract
There is evidence that fibroblast growth factors (FGFs) are involved in the regulation of growth and regression of the corpus luteum (CL). However, the expression pattern of most FGF receptors (FGFRs) during CL lifespan is still unknown. The objective of the present study was to determine the pattern of expression of ‘B’ and ‘C’ splice variants of FGFRs in the bovine CL. Bovine CL were collected from an abattoir and classed as corpora hemorrhagica (Stage I), developing (Stage II), developed (Stage III) or regressed (Stage IV) CL. Expression of FGFR mRNA was measured by semiquantitative reverse transcription-polymerase chain reaction and FGFR protein was localised by immunohistochemistry. Expression of mRNA encoding the ‘B’ and ‘C’ spliced forms of FGFR1 and FGFR2 was readily detectable in the bovine CL and was accompanied by protein localisation. FGFR1C and FGFR2C mRNA expression did not vary throughout CL lifespan, whereas FGFR1B was upregulated in the developed (Stage III) CL. FGFR3B, FGFR3C and FGFR4 expression was inconsistent in the bovine CL. The present data indicate that FGFR1 and FGFR2 splice variants are the main receptors for FGF action in the bovine CL.
Collapse
|
835
|
Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, Gnanapragasam VJ. Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 2007; 213:82-90. [PMID: 17607666 DOI: 10.1002/path.2205] [Citation(s) in RCA: 89] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Fibroblast growth factor receptors (FGFRs) mediate the tumourigenic effects of FGFs in prostate cancer. These receptors are therefore potential therapeutic targets in the development of inhibitors to this pathway. To identify the most relevant targets, we simultaneously investigated FGFR1-4 expression using a prostate cancer tissue microarray (TMA) and in laser capture microdissected (LCM) prostate epithelial cells. In malignant prostates (n = 138) we observed significant FGFR1 and FGFR4 protein over-expression in comparison with benign prostates (n = 58; p < 0.0001). FGFR1 was expressed at high levels in the majority of tumours (69% of grade 3 or less, 74% of grade 4 and 70% of grade 5), while FGFR4 was strongly expressed in 83% of grade 5 cancers but in only 25% of grade 1-3 cancers (p < 0.0001). At the transcript level we observed a similar pattern, with FGFR1 and FGFR4 mRNA over-expressed in malignant epithelial cells compared to benign cells (p < 0.0005 and p < 0.05, respectively). While total FGFR2 was increased in some cancers, there was no association between expression and tumour grade or stage. Transcript analysis, however, revealed a switch in the predominant isoform expressed from FGFR2IIIb to FGFR2IIIc among malignant epithelial cells. In contrast, protein and transcript expression of FGFR3 was very similar between benign and cancer biopsies. The functional effect of targeting FGFR4 in prostate cancer cells has not previously been investigated. In in vitro experiments, suppression of FGFR4 by RNA interference effectively blocked prostate cancer cell proliferation (p < 0.0001) and invasion (p < 0.001) in response to exogenous stimulation. This effect was evident regardless of whether the cells expressed the FGFR4 Arg388 or Gly388 allele. In parallel experiments, FGFR3 suppression had no discernible effect on cancer cell behaviour. These results suggest evidence of selective over-expression of FGFR1 and FGFR4 in clinical prostate cancer and support the notion of targeted inhibition of these receptors to disrupt FGF signalling.
Collapse
MESH Headings
- Case-Control Studies
- Cell Line, Tumor
- Cell Proliferation
- Gene Expression Profiling
- Gene Expression Regulation, Neoplastic
- Humans
- Immunohistochemistry
- Male
- Microdissection
- Microscopy, Confocal
- Oligonucleotide Array Sequence Analysis
- Polymorphism, Single Nucleotide
- Prostatic Neoplasms/genetics
- Prostatic Neoplasms/metabolism
- Protein Isoforms/genetics
- RNA Interference
- RNA, Small Interfering/pharmacology
- Receptor, Fibroblast Growth Factor, Type 1/analysis
- Receptor, Fibroblast Growth Factor, Type 1/genetics
- Receptor, Fibroblast Growth Factor, Type 1/metabolism
- Receptor, Fibroblast Growth Factor, Type 2/analysis
- Receptor, Fibroblast Growth Factor, Type 2/genetics
- Receptor, Fibroblast Growth Factor, Type 2/metabolism
- Receptor, Fibroblast Growth Factor, Type 3/analysis
- Receptor, Fibroblast Growth Factor, Type 3/genetics
- Receptor, Fibroblast Growth Factor, Type 3/metabolism
- Receptor, Fibroblast Growth Factor, Type 4/analysis
- Receptor, Fibroblast Growth Factor, Type 4/genetics
- Receptor, Fibroblast Growth Factor, Type 4/metabolism
- Receptors, Fibroblast Growth Factor/analysis
- Receptors, Fibroblast Growth Factor/genetics
- Receptors, Fibroblast Growth Factor/metabolism
- Transcription, Genetic
Collapse
Affiliation(s)
- K Sahadevan
- Urology Research Group, Northern Institute for Cancer Research, Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK
| | | | | | | | | | | |
Collapse
|
836
|
Abstract
Members of the fibroblast growth factor (FGF) family are believed to play critical roles during organogenesis and carcinogenesis via signaling between epithelial and stromal compartments. Two new studies in this issue of Cancer Cell underscore the importance of FGF signaling in mediating epithelial-stromal interactions during prostate carcinogenesis. These papers show that deregulated FGF signaling in mouse models of prostate cancer leads to cancer progression and promotes an epithelial-mesenchymal transition, suggesting that FGF receptor inhibitors may have therapeutic value for prostate cancer treatment.
Collapse
Affiliation(s)
- Cory Abate-Shen
- Department of Urology, Columbia University College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, New York, NY 10032, USA.
| | | |
Collapse
|
837
|
Memarzadeh S, Xin L, Mulholland DJ, Mansukhani A, Wu H, Teitell MA, Witte ON. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 2007; 12:572-85. [PMID: 18068633 PMCID: PMC2931420 DOI: 10.1016/j.ccr.2007.11.002] [Citation(s) in RCA: 142] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/08/2007] [Revised: 07/16/2007] [Accepted: 11/01/2007] [Indexed: 02/07/2023]
Abstract
Enhanced mesenchymal expression of FGF10 led to the formation of multifocal PIN or prostate cancer. Inhibition of epithelial FGFR1 signaling using DN FGFR1 led to reversal of the cancer phenotype. A subset of the FGF10-induced carcinoma was serially transplantable. Paracrine FGF10 led to an increase in epithelial androgen receptor and synergized with cell-autonomous activated AKT. Our observations indicate that stromal FGF10 expression may facilitate the multifocal histology observed in prostate adenocarcinoma and suggest the FGF10/FGFR1 axis as a potential therapeutic target in treating hormone-sensitive or refractory prostate cancer. We also show that transient exposure to a paracrine growth factor may be sufficient for the initiation of oncogenic transformation.
Collapse
Affiliation(s)
- Sanaz Memarzadeh
- Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
| | | | | | | | | | | | | |
Collapse
|
838
|
Nakayama Y, Miyake A, Nakagawa Y, Mido T, Yoshikawa M, Konishi M, Itoh N. Fgf19 is required for zebrafish lens and retina development. Dev Biol 2007; 313:752-66. [PMID: 18089288 DOI: 10.1016/j.ydbio.2007.11.013] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2007] [Revised: 11/06/2007] [Accepted: 11/09/2007] [Indexed: 02/01/2023]
Abstract
Fgf signaling plays crucial roles in morphogenesis. Fgf19 is required for zebrafish forebrain development. Here, we examined the roles of Fgf19 in the formation of the lens and retina in zebrafish. Knockdown of Fgf19 caused a size reduction of the lens and the retina, failure of closure of the choroids fissure, and a progressive expansion of the retinal tissue to the midline of the forebrain. Fgf19 expressed in the nasal retina and lens was involved in cell survival but not cell proliferation during embryonic lens and retina development. Fgf19 was essential for the differentiation of lens fiber cells in the lens but not for the neuronal differentiation and lamination in the retina. Loss of nasal fate in the retina caused by the knockdown of Fgf19, expansion of nasal fate in the retina caused by the overexpression of Fgf19 and eye transplantation indicated that Fgf19 in the retina was crucial for the nasal-temporal patterning of the retina that is critical for the guidance of retinal ganglion cell axons. Knockdown of Fgf19 also caused incorrect axon pathfinding. The present findings indicate that Fgf19 positively regulates the patterning and growth of the retina, and the differentiation and growth of the lens in zebrafish.
Collapse
Affiliation(s)
- Yoshiaki Nakayama
- Department of Genetic Biochemistry, Kyoto University Graduate School of Pharmaceutical Sciences, Sakyo, Kyoto 606-8501, Japan
| | | | | | | | | | | | | |
Collapse
|
839
|
Itoh N. The Fgf families in humans, mice, and zebrafish: their evolutional processes and roles in development, metabolism, and disease. Biol Pharm Bull 2007; 30:1819-25. [PMID: 17917244 DOI: 10.1248/bpb.30.1819] [Citation(s) in RCA: 159] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Fibroblast growth factors (Fgfs) were originally isolated as growth factors for fibroblasts. However, Fgfs are now recognized as polypeptide growth factors of ca. 150-250 amino acid residues with diverse biological activities and expression profiles. The Fgf signaling system has been identified in multicelluar but not in unicellular organisms. In contrast to the only two Fgf genes and one Fgf receptor (Fgfr) gene in Caenorhabditis elegans, both the human and mouse Fgf and Fgfr gene families comprise twenty-two and four members, respectively. Their evolutional processes indicate that the Fgf and Fgfr gene families greatly co-expanded during the evolution of early vertebrates. The expansion of the Fgf and Fgfr gene families has enabled this signaling system to acquire diversity of function and a nearly ubiquitous involvement in many developmental and physiological processes. The zebrafish fgf gene family comprises twenty-seven members with several paralogs generated by an additional genome duplication. The mouse and zebrafish are useful models for studying gene functions. Fgf knockout mice have been generated. Several Fgf knockout mice die in the embryonic or early postnatal stages, indicating crucial roles for these genes in various developmental processes. However, other Fgf knockout mice survive with subtle phenotypic alterations. Their functions might be redundant. Studies using zebrafish embryos with mutated or knockdown fgfs also indicate that fgfs play crucial roles in development in that species. Although most Fgfs act in development in a paracrine and/or autocrine manner, some have potential roles in metabolism in an endocrine manner. In humans, Fgf signaling disorders result in hereditary diseases and cancers.
Collapse
Affiliation(s)
- Nobuyuki Itoh
- Department of Genetic Biochemistry, Kyoto University Graduate School of Pharmaceutical Sciences, Sakyo-ku, Kyoto, Japan.
| |
Collapse
|
840
|
Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, Mohammadi M, Futreal PA, Stratton MR, Trent JM, Goodfellow PJ. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007; 26:7158-62. [PMID: 17525745 PMCID: PMC2871595 DOI: 10.1038/sj.onc.1210529] [Citation(s) in RCA: 229] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2007] [Revised: 03/07/2007] [Accepted: 03/30/2007] [Indexed: 02/06/2023]
Abstract
Endometrial carcinoma is the most common gynecological malignancy in the United States. Although most women present with early disease confined to the uterus, the majority of persistent or recurrent tumors are refractory to current chemotherapies. We have identified a total of 11 different FGFR2 mutations in 3/10 (30%) of endometrial cell lines and 19/187 (10%) of primary uterine tumors. Mutations were seen primarily in tumors of the endometrioid histologic subtype (18/115 cases investigated, 16%). The majority of the somatic mutations identified were identical to germline activating mutations in FGFR2 and FGFR3 that cause Apert Syndrome, Beare-Stevenson Syndrome, hypochondroplasia, achondroplasia and SADDAN syndrome. The two most common somatic mutations identified were S252W (in eight tumors) and N550K (in five samples). Four novel mutations were identified, three of which are also likely to result in receptor gain-of-function. Extensive functional analyses have already been performed on many of these mutations, demonstrating they result in receptor activation through a variety of mechanisms. The discovery of activating FGFR2 mutations in endometrial carcinoma raises the possibility of employing anti-FGFR molecularly targeted therapies in patients with advanced or recurrent endometrial carcinoma.
Collapse
Affiliation(s)
- P M Pollock
- Cancer and Cell Biology Division, Translational Genomics Research Institute, Phoenix, AZ, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
841
|
Puligilla C, Feng F, Ishikawa K, Bertuzzi S, Dabdoub A, Griffith AJ, Fritzsch B, Kelley MW. Disruption of fibroblast growth factor receptor 3 signaling results in defects in cellular differentiation, neuronal patterning, and hearing impairment. Dev Dyn 2007; 236:1905-17. [PMID: 17557302 PMCID: PMC3904742 DOI: 10.1002/dvdy.21192] [Citation(s) in RCA: 104] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
Deletion of fibroblast growth factor receptor 3 (Fgfr3) leads to hearing impairment in mice due to defects in the development of the organ of Corti, the sensory epithelium of the Cochlea. To examine the role of FGFR3 in auditory development, cochleae from Fgfr3(-/-) mice were examined using anatomical and physiological methods. Deletion of Fgfr3 leads to the absence of inner pillar cells and an increase in other cell types, suggesting that FGFR3 regulates cell fate. Defects in outer hair cell differentiation were also observed and probably represent the primary basis for hearing loss. Furthermore, innervation defects were detected consistent with changes in the fiber guidance properties of pillar cells. To elucidate the mechanisms underlying the effects of FGFR3, we examined the expression of Bmp4, a known target. Bmp4 was increased in Fgfr3(-/-) cochleae, and exogenous application of bone morphogenetic protein 4 (BMP4) onto cochlear explants induced a significant increase in the outer hair cells, suggesting the Fgf and Bmp signaling act in concert to pattern the cochlea.
Collapse
|
842
|
Fibroblast growth factor receptor 2 regulates proliferation and Sertoli differentiation during male sex determination. Proc Natl Acad Sci U S A 2007; 104:16558-63. [PMID: 17940049 DOI: 10.1073/pnas.0702581104] [Citation(s) in RCA: 126] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Targeted mutagenesis of Fgf9 in mice causes male-to-female sex reversal. Among the four FGF receptors, FGFR2 showed two highly specific patterns based on antibody staining, suggesting that it might be the receptor-mediating FGF9 signaling in the gonad. FGFR2 was detected at the plasma membrane in proliferating coelomic epithelial cells and in the nucleus in Sertoli progenitor cells. This expression pattern suggested that Fgfr2 might play more than one role in testis development. To test the hypothesis that Fgfr2 is required for male sex determination, we crossed mice carrying a floxed allele of Fgfr2 with two different Cre lines to induce a temporal or cell-specific deletion of this receptor. Results show that deletion of Fgfr2 in embryonic gonads phenocopies deletion of Fgf9 and leads to male-to-female sex reversal. Using these two Cre lines, we provide the first genetic evidence that Fgfr2 plays distinct roles in proliferation and Sertoli cell differentiation during testis development.
Collapse
|
843
|
Knowles MA. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol 2007; 25:581-93. [PMID: 17912529 PMCID: PMC4876910 DOI: 10.1007/s00345-007-0213-4] [Citation(s) in RCA: 86] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2007] [Accepted: 08/27/2007] [Indexed: 10/22/2022] Open
Abstract
Although non-invasive bladder tumours (pTa) are the most common group of bladder tumours at presentation, there has until recently been relatively little information on their molecular biology. Thus it was of great interest when mutations in the FGF receptor 3 (FGFR3) were identified in bladder tumours and it became apparent that these were most common in tumours of low grade and stage. Since the initial description of activating mutations of FGFR3, there have been numerous studies confirming the frequency and spectrum of these mutations in bladder cancers of all grades and stages. Mutation screening techniques have evolved and improved. FGFR3 mutation has been assessed as a predictive biomarker in tumour tissues and as a diagnostic biomarker in urine. Efforts have been made to understand the function of FGFR3 in urothelial and other cells. Although our understanding of FGFR3 function is incomplete, it is already apparent that this may represent an important therapeutic target not only in non-invasive bladder cancer but also in a significant number of invasive tumours. This review summarises the current state of knowledge of this interesting receptor in urothelial carcinoma (UC).
Collapse
Affiliation(s)
- Margaret A Knowles
- Cancer Research UK Clinical Centre, Section of Oncology, Leeds Institute of Molecular Medicine, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK.
| |
Collapse
|
844
|
Wu X, Ge H, Gupte J, Weiszmann J, Shimamoto G, Stevens J, Hawkins N, Lemon B, Shen W, Xu J, Veniant MM, Li YS, Lindberg R, Chen JL, Tian H, Li Y. Co-receptor Requirements for Fibroblast Growth Factor-19 Signaling. J Biol Chem 2007; 282:29069-72. [PMID: 17711860 DOI: 10.1074/jbc.c700130200] [Citation(s) in RCA: 110] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
FGF19 is a unique member of the fibroblast growth factor (FGF) family of secreted proteins that regulates bile acid homeostasis and metabolic state in an endocrine fashion. Here we investigate the cell surface receptors required for signaling by FGF19. We show that betaKlotho, a single-pass transmembrane protein highly expressed in liver and fat, induced ERK1/2 phosphorylation in response to FGF19 treatment and significantly increased the interactions between FGF19 and FGFR4. Interestingly, our results show that alphaKlotho, another Klotho family protein related to betaKlotho, also induced ERK1/2 phosphorylation in response to FGF19 treatment and increased FGF19-FGFR4 interactions in vitro, similar to the effects of betaKlotho. In addition, heparin further enhanced the effects of both alphaKlotho and betaKlotho in FGF19 signaling and interaction experiments. These results suggest that a functional FGF19 receptor may consist of FGF receptor (FGFR) and heparan sulfate complexed with either alphaKlotho or betaKlotho.
Collapse
Affiliation(s)
- Xinle Wu
- Amgen Inc., South San Francisco, California 94080, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
845
|
Huang X, Yang C, Luo Y, Jin C, Wang F, McKeehan WL. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 2007; 56:2501-10. [PMID: 17664243 DOI: 10.2337/db07-0648] [Citation(s) in RCA: 109] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVE Fibroblast growth factor (FGF) family signaling largely controls cellular homeostasis through short-range intercell paracrine communication. Recently FGF15/19, 21, and 23 have been implicated in endocrine control of metabolic homeostasis. The identity and location of the FGF receptor isotypes that mediate these effects are unclear. The objective was to determine the role of FGFR4, an isotype that has been proposed to mediate an ileal FGF15/19 to hepatocyte FGFR4 axis in cholesterol homeostasis, in metabolic homeostasis in vivo. RESEARCH DESIGN AND METHODS FGFR4(-/-) mice-mice overexpressing constitutively active hepatic FGFR4--and FGFR4(-/-) with constitutively active hepatic FGFR4 restored in the liver were subjected to a normal and a chronic high-fat diet sufficient to result in obesity. Systemic and liver-specific metabolic phenotypes were then characterized. RESULTS FGFR4-deficient mice on a normal diet exhibited features of metabolic syndrome that include increased mass of white adipose tissue, hyperlipidemia, glucose intolerance, and insulin resistance, in addition to hypercholesterolemia. Surprisingly, the FGFR4 deficiency alleviated high-fat diet-induced fatty liver in obese mice, which is also a correlate of metabolic syndrome. Restoration of FGFR4, specifically in hepatocytes of FGFR4-deficient mice, decreased plasma lipid levels and restored the high-fat diet-induced fatty liver but failed to restore glucose tolerance and sensitivity to insulin. CONCLUSIONS FGFR4 plays essential roles in systemic lipid and glucose homeostasis. FGFR4 activity in hepatocytes that normally serves to prevent systemic hyperlipidemia paradoxically underlies the fatty liver disease associated with chronic high-fat intake and obesity.
Collapse
Affiliation(s)
- Xinqiang Huang
- Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M Health Science Center, 2121 W. Holcombe Blvd., Houston, TX 77030, USA
| | | | | | | | | | | |
Collapse
|
846
|
Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-O M. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007; 282:26687-26695. [PMID: 17623664 PMCID: PMC2496965 DOI: 10.1074/jbc.m704165200] [Citation(s) in RCA: 582] [Impact Index Per Article: 34.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
The fibroblast growth factor (FGF) 19 subfamily of ligands, FGF19, FGF21, and FGF23, function as hormones that regulate bile acid, fatty acid, glucose, and phosphate metabolism in target organs through activating FGF receptors (FGFR1-4). We demonstrated that Klotho and betaKlotho, homologous single-pass transmembrane proteins that bind to FGFRs, are required for metabolic activity of FGF23 and FGF21, respectively. Here we show that, like FGF21, FGF19 also requires betaKlotho. Both FGF19 and FGF21 can signal through FGFR1-3 bound by betaKlotho and increase glucose uptake in adipocytes expressing FGFR1. Additionally, both FGF19 and FGF21 bind to the betaKlotho-FGFR4 complex; however, only FGF19 signals efficiently through FGFR4. Accordingly, FGF19, but not FGF21, activates FGF signaling in hepatocytes that primarily express FGFR4 and reduces transcription of CYP7A1 that encodes the rate-limiting enzyme for bile acid synthesis. We conclude that the expression of betaKlotho, in combination with particular FGFR isoforms, determines the tissue-specific metabolic activities of FGF19 and FGF21.
Collapse
Affiliation(s)
- Hiroshi Kurosu
- Department of Pathology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390
| | - Mihwa Choi
- Department of Molecular Biology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390
| | - Yasushi Ogawa
- Department of Pathology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390
| | - Addie S Dickson
- Department of Pathology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390
| | - Regina Goetz
- Department of Pharmacology, New York University School of Medicine, New York, New York 10016
| | - Anna V Eliseenkova
- Department of Pharmacology, New York University School of Medicine, New York, New York 10016
| | - Moosa Mohammadi
- Department of Pharmacology, New York University School of Medicine, New York, New York 10016
| | - Kevin P Rosenblatt
- Department of Pathology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390
| | - Steven A Kliewer
- Department of Molecular Biology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390
| | - Makoto Kuro-O
- Department of Pathology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390.
| |
Collapse
|
847
|
Lange C, Ehlken C, Martin G, Konzok K, Moscoso Del Prado J, Hansen LL, Agostini HT. Intravitreal injection of the heparin analog 5-amino-2-naphthalenesulfonate reduces retinal neovascularization in mice. Exp Eye Res 2007; 85:323-7. [PMID: 17662276 DOI: 10.1016/j.exer.2007.05.007] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2006] [Revised: 05/29/2007] [Accepted: 05/30/2007] [Indexed: 11/16/2022]
Abstract
The effect of the heparin analog 5-amino-2-naphthalenesulfonate (5-amino-2-NMS) on retinal neovascularization was investigated in the mouse model for oxygen-induced retinopathy (OIR). From postnatal day 7 (P7) until P12, mice were kept in a 75% oxygen environment. On P12, they received an intravitreal injection of 10mM 5-amino-2-NMS in one eye and PBS as control substance in the fellow eye. The animals were intracardially perfused with fluorescein-dextran solution on P17. Retinal whole mounts were prepared and ischemic retinopathy was evaluated in 30 animals using a standardized retinopathy score. A single intravitreal injection of 5-amino-2-NMS reduces significantly angioproliferative changes (blood vessel tufts, extra-retinal neovascularization, and blood vessel tortuosity) compared to the contralateral control eye (p=0.025). The median retinopathy score (maximal 13) for the 5-amino-2-NMS treated eyes was 6 versus 8 for the control eyes. 5-Amino-2-NMS binds to the heparin-binding site of FGF1 and FGF2 and thus may be a promising substance for the local treatment of retinal neovascularization.
Collapse
Affiliation(s)
- Clemens Lange
- Augenklinik, Universitätsklinikum Freiburg, Killianstrasse 5, 79106 Freiburg, Germany
| | | | | | | | | | | | | |
Collapse
|
848
|
Kehler JS, David VA, Schäffer AA, Bajema K, Eizirik E, Ryugo DK, Hannah SS, O'Brien SJ, Menotti-Raymond M. Four independent mutations in the feline fibroblast growth factor 5 gene determine the long-haired phenotype in domestic cats. J Hered 2007; 98:555-66. [PMID: 17767004 PMCID: PMC3756544 DOI: 10.1093/jhered/esm072] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
To determine the genetic regulation of "hair length" in the domestic cat, a whole-genome scan was performed in a multigenerational pedigree in which the "long-haired" phenotype was segregating. The 2 markers that demonstrated the greatest linkage to the long-haired trait (log of the odds > or = 6) flanked an estimated 10-Mb region on cat chromosome B1 containing the Fibroblast Growth Factor 5 (FGF5) gene, a candidate gene implicated in regulating hair follicle growth cycle in other species. Sequence analyses of FGF5 in 26 cat breeds and 2 pedigrees of nonbreed cats revealed 4 separate mutations predicted to disrupt the biological activity of the FGF5 protein. Pedigree analyses demonstrated that different combinations of paired mutant FGF5 alleles segregated with the long-haired phenotype in an autosomal recessive manner. Association analyses of more than 380 genotyped breed and nonbreed cats were consistent with mutations in the FGF5 gene causing the long-haired phenotype in an autosomal recessive manner. In combination, these genomic approaches demonstrated that FGF5 is the major genetic determinant of hair length in the domestic cat.
Collapse
Affiliation(s)
- James S Kehler
- The Laboratory of Genomic Diversity, National Cancer Institute-Frederick, Frederick, MD 21702, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
849
|
Saarimäki-Vire J, Peltopuro P, Lahti L, Naserke T, Blak AA, Vogt Weisenhorn DM, Yu K, Ornitz DM, Wurst W, Partanen J. Fibroblast growth factor receptors cooperate to regulate neural progenitor properties in the developing midbrain and hindbrain. J Neurosci 2007; 27:8581-92. [PMID: 17687036 PMCID: PMC6672929 DOI: 10.1523/jneurosci.0192-07.2007] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
Fibroblast growth factors (FGFs) secreted from the midbrain-rhombomere 1 (r1) boundary instruct cell behavior in the surrounding neuroectoderm. For example, a combination of FGF and sonic hedgehog (SHH) can induce the development of the midbrain dopaminergic neurons, but the mechanisms behind the action and integration of these signals are unclear. We studied how FGF receptors (FGFRs) regulate cellular responses by analyzing midbrain-r1 development in mouse embryos, which carry different combinations of mutant Fgfr1, Fgfr2, and Fgfr3 alleles. Our results show that the FGFRs act redundantly to support cell survival in the dorsal neuroectoderm, promote r1 tissue identity, and regulate the production of ventral neuronal populations, including midbrain dopaminergic neurons. The compound Fgfr mutants have apparently normal WNT/SHH signaling and neurogenic gene expression in the ventral midbrain, but the number of proliferative neural progenitors is reduced as a result of precocious neuronal differentiation. Our results suggest a SoxB1 family member, Sox3, as a potential FGF-induced transcription factor promoting progenitor renewal. We propose a model for regulation of progenitor cell self-renewal and neuronal differentiation by combinatorial intercellular signals in the ventral midbrain.
Collapse
Affiliation(s)
- Jonna Saarimäki-Vire
- Institute of Biotechnology, Viikki Biocenter, University of Helsinki, 00014 Helsinki, Finland
| | - Paula Peltopuro
- Institute of Biotechnology, Viikki Biocenter, University of Helsinki, 00014 Helsinki, Finland
| | - Laura Lahti
- Institute of Biotechnology, Viikki Biocenter, University of Helsinki, 00014 Helsinki, Finland
| | - Thorsten Naserke
- National Research Center for Environment and Health, Institute of Developmental Genetics, D-85764 Neuherberg, Germany
- Max Planck Institute of Psychiatry, D-80804 Munich, Germany, and
| | - Alexandra A. Blak
- National Research Center for Environment and Health, Institute of Developmental Genetics, D-85764 Neuherberg, Germany
- Max Planck Institute of Psychiatry, D-80804 Munich, Germany, and
| | - Daniela M. Vogt Weisenhorn
- National Research Center for Environment and Health, Institute of Developmental Genetics, D-85764 Neuherberg, Germany
- Max Planck Institute of Psychiatry, D-80804 Munich, Germany, and
| | - Kai Yu
- Department of Molecular Biology and Pharmacology, Washington University Medical School, St. Louis, Missouri 63110
| | - David M. Ornitz
- Department of Molecular Biology and Pharmacology, Washington University Medical School, St. Louis, Missouri 63110
| | - Wolfgang Wurst
- National Research Center for Environment and Health, Institute of Developmental Genetics, D-85764 Neuherberg, Germany
- Max Planck Institute of Psychiatry, D-80804 Munich, Germany, and
| | - Juha Partanen
- Institute of Biotechnology, Viikki Biocenter, University of Helsinki, 00014 Helsinki, Finland
| |
Collapse
|
850
|
Zhang Y, Sawada T, Jing X, Yokote H, Yan X, Sakaguchi K. Regulation of ephexin1, a guanine nucleotide exchange factor of Rho family GTPases, by fibroblast growth factor receptor-mediated tyrosine phosphorylation. J Biol Chem 2007; 282:31103-12. [PMID: 17702745 DOI: 10.1074/jbc.m704430200] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Fibroblast growth factor (FGF) signal is implicated in not only cell proliferation, but cell migration and morphological changes. Several different Rho family GTPases downstream of the Ras/ERK pathway are postulated to mediate the latter functions. However, none have been recognized to be directly coupled to FGF receptors (FGFRs). We have previously reported that EphA4 and FGFRs hetero-oligomerize through their cytoplasmic domains, trans-activate each other, and transduce a signal for cell proliferation through a docking protein, FRS2alpha (Yokote, H., Fujita, K., Jing, X., Sawada, T., Liang, S., Yao, L., Yan, X., Zhang, Y., Schlessinger, J., and Sakaguchi, K. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 18866-18871). Here, we have found that ephexin1, a guanine nucleotide exchange factor for Rho family GTPases, constitutes another downstream component of the receptor complex. Ephexin1 directly binds to the kinase domain of FGFR mainly through its DH and PH domains. The binding appears to become weaker and limited to the DH domain when FGFRs become activated. FGFR-mediated phosphorylation of ephexin1 enhances the guanine nucleotide exchange activity toward RhoA without affecting the activity to Rac1 or Cdc42. The FGFR-mediated tyrosine phosphorylation includes, but is not limited to, the residue (Tyr-87) phosphorylated by Src family kinase, which is known to be activated following EphA4 activation. The Tyr-to-Asp mutations that mimic the tyrosine phosphorylation in some of the putative FGFR-mediated phosphorylation sites increase the nucleotide exchange activity for RhoA without changing the activity for Rac1 or Cdc42. From these results, we conclude that ephexin1 is located immediately downstream of the EphA4-FGFR complex and the function is altered by the FGFR-mediated tyrosine phosphorylation at multiple sites.
Collapse
Affiliation(s)
- Yueqiang Zhang
- Department of Molecular Cell Biology, Institute of Advanced Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama 641-8509, Japan
| | | | | | | | | | | |
Collapse
|